RELAPSE İN DRUG-SENSİTİVE PULMONARY TB PATİENTS Üsküdar Dispenser ………….Dr. Bektaş Kısa Beykoz Dispenser………… Dr. Sinem Köyman Kumkapı Dispenser………… Dr. Canan Küçük Şehremini Dispenser…………Dr. Nesrin Sarımurat İ. U. İstanbul Medical Faculty…..Prof. Dr. Zeki Kılıçaslan

Aim The aim of this retrospective study is to determine the relapse rates in TB patients.

Findings Total number of patients (pulmonary + extrapulmonary ) 1100 Treatment success rate for all patients % 91,5 (1007/1100) Cure rate for smear (+) new patients %85,7 (373/435) Kumkapı VSD Şehremini VSD Beykoz VSD Üsküdar VSD

Material andMethod

Material and Method All patients were contacted by telephone, those who were not reached had letters sent by mail. Those who had no clinical complaint or stabil x-rays were accepted as no relapse. 18 suspicious patients were evaluated with smears which were negative. Some patients who repeatedly stated they had no complaints were unable to come to the dispensers. These patients family members were questioned and verified the patients good health.

Material and Method

Material and Method

Method Thoses who were drug resistant or not tested were left out of this study.

Material and Method

414 olgu : 21,7 ay Material and Method Pulmonary TB, Smear (+) and/or Culture (+), Drug-sensitive patients, 414 olgu : Average age : 36,6 (11-80) Average follow up period after treatment : 21,7 ay

Material and Method

Findings DOTS Partial or no DOTS Total New patients % 0,9 % 1,7 % 1,2 % 0,9 (2/226) % 1,7 (2/120) (P> 0,05) % 1,2 (4/346) Previously treated patients % 2,4 (1/42) % 11,1 (3/27) (P>0,05) % 5,9 (4/68) RELAPS 3 patients 5 patients % 1,9 (8/414) NOT: The Ficher test was used for the determination of data differences

All relaps patients were proven with smear or culture positivity. Findings Smear (+) Smear (-) Culture (+) TOTAL NEW 2 4 PREVİOUSLY TREATED 8 All relaps patients were proven with smear or culture positivity.

Conclusion İn this study; Four İstanbul dispensers with an average treatment success rate of 91.5% have acceptable relaps rates. With DOT relaps rates were found to be lower (although not statistically significant) especially in previously treated patients.